G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference
RESEARCH TRIANGLE PARK, N.C., May 18, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive Officer, will provide a virtual corporate presentation during the H.C. Wainwright & Co. Global Investment Conference. The presentation will become available at 7:00 AM EDT on May 24, 2022. This meeting is being held in person and virtually; the webcast of G1’s presentation will be accessible on the of .
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage oncology company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit and follow us on Twitter .
Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
